التفاصيل البيبلوغرافية
العنوان:
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
المؤلفون:
Yale, Jf , Bakris, G , Cariou, B , Nieto, J , David Neto, E , Yue, D , Wajs, E , Figueroa, K , Jiang, J , Law, G , Usiskin, K , Meininger, G , DIA3004 Study Group , Ansari, A , Arnouts, P , Assefi, A , Barreto, A , Barysheva, O , Bavanandam, S , Blaze, K , Bochenek, A , Bononi, P , Booth, W , Boyarkin, M , Burgess, L , Busch, K , Buse, J , Carranza, J , Cha, B , Chang, A , Clavel, S , Cockrell, Rc , Conway, J , Cook, W , Dande, A , De Los Rios MO , Deshmukh, V , Dobjanschi, C , Dotta, Francesco , Elliott, T , Ellis, G , Ferraro, R , Fishman, N , Fomin, V , Fraige Filho, F , Gagiu, R , Goh, Bl , Goldenberg, R , Gorriz, Jl , Gottschlich, G , Gouet, D , Grenfell, R , Griffin, C , Guarisco, M , Guerci, B , Henkel, E , Hramiak, I , Ison, R , Jadoul, M , Jang, H , Januszewicz, A , Kale, S , Karpova, I , Kaye, W , Kerstein, H , Kijanska, J , Kobalava, Z , Kong, N , Krasilnikova, E , Krebs, J , Kuczerowski, R , Kuzin, A , Kuzmenko, A , Laurens, W , Lim, Sk , Marasaev, V , Castelao, Am , Merker, L , Michlin, B , Morales, E , Motylev, I , Muse, D , Mutha, A , Neto, Ed , Nicholls, K , Niemetz, I , Iglesias, Jn , Ong, Lm , Onor, G , Packham, D , Petit, C , Piatti, M , Pirags, V , Poch, E , Ramirez, G , Riser, J , Roger, S , Ross, S , Rudolph, L , Sangumani, J , Schollum, J , Scott, R , Sebopa, B , Serafinceanu, C , Serusclat, P , Seufert, J , Siegmund, T , Silva, A , Skokowska, E , Smith, D , Sokolova, J , Solovyov, O , Steindorf, J , Stringam, S , Teterovska, D , Thivolet, C , Tytus, R , Vally, T , Van Vlem, B , Vercammen, C , Volkova, N , Warling, X , Winkler, L , Young, S , Zanella, Mt , Zimmerer, M.
المصدر:
Diabetes, Obesity and Metabolism . 16:1016-1027
بيانات النشر:
Wiley, 2014.
سنة النشر:
2014
مصطلحات موضوعية:
Blood Glucose , Male , medicine.medical_specialty , Endocrinology, Diabetes and Metabolism , Urinary system , Urology , Renal function , Blood Pressure , Thiophenes , Placebo , Drug Administration Schedule , Diabetic nephropathy , chemistry.chemical_compound , Endocrinology , Double-Blind Method , Glucosides , Sodium-Glucose Transporter 2 , Internal medicine , Internal Medicine , medicine , Humans , Hypoglycemic Agents , Diabetic Nephropathies , Canagliflozin , Renal Insufficiency, Chronic , Sodium-Glucose Transporter 2 Inhibitors , Aged , Creatinine , business.industry , Body Weight , medicine.disease , Treatment Outcome , Blood pressure , Diabetes Mellitus, Type 2 , chemistry , Disease Progression , Female , business , Glomerular Filtration Rate , Kidney disease , medicine.drug
الوصف:
Aim This study evaluated the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and within a subset of Stage 3 chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR] ≥30 and
تدمد:
1462-8902
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae750653397d536ccc4fe947ed11e42Test https://doi.org/10.1111/dom.12348Test
حقوق:
CLOSED
رقم الانضمام:
edsair.doi.dedup.....5ae750653397d536ccc4fe947ed11e42
قاعدة البيانات:
OpenAIRE
